SteinCares and Shilpa Biologicals Collaborate to Boost Biosimilar Access in Latin America

Strategic Partnership to Enhance Biosimilar Access in Latin America

In an exciting development for healthcare in Latin America, SteinCares, a prominent specialist medical company, has announced a licensing agreement with Shilpa Biologicals Pvt. Ltd. (SBPL). This partnership aims to significantly increase access to biosimilars across the region, providing cost-effective treatment options to patients.

SteinCares holds a reputable position in the biopharmaceutical sector in Latin America, and now, with this collaboration, they aim to leverage their established market presence alongside SBPL's advanced development and manufacturing capabilities.

Details of the Collaboration

Under this agreement, SteinCares will gain exclusive rights to register, market, and distribute a biosimilar throughout Latin America, while Shilpa Biologicals will be responsible for product development and commercial production at their facility in Dharwad, India. This dual approach combines the strengths of both companies: SteinCares' robust local marketing platform and SBPL’s proficiency in biopharmaceutical processes.

Mitchell Waserstein, the CEO of SteinCares, expressed enthusiasm about the partnership, stating, "We are excited to partner with Shilpa Biologicals to bring this biosimilar to Latin America. This agreement reinforces our leadership role in the biosimilars sector and positions us as a strategic ally for global pharmaceutical firms looking to navigate the complicated health markets of Latin America."

Aimed at Expanding Patient Access

The overarching goal of this agreement is to enhance patients' access to safe, innovative, and affordable treatments throughout Latin America. Dr. Sridevi Khambhampaty, CEO of Shilpa Biologicals, commented on their strategic entry into the Latin American market: "This partnership is pivotal in our mission to expand patient access to reliable treatments across the region. Our collaboration is poised to create substantial value not just for the patients, but also for healthcare systems and our organizations as we grow our presence in the biosimilar domain."

The partnership marks a significant milestone as it is the first product emerging from this strategic collaboration, highlighting Shilpa Biologicals' entry into the Latin American market.

SteinCares: A Leading Provider in Specialty Medicine

SteinCares is dedicated to expanding access to innovative treatments across 30 countries in Latin America. With an impressive track record of over 45 years in the sector, the company offers a one-stop-shop platform that pioneers biosimilar therapies.

In contrast, Shilpa Biologicals introduces an integrated biopharmaceutical approach, showcasing a hybrid model that focuses on development and manufacturing. They deliver capabilities essential for formulating licensed formulations in critical health areas such as immunology, oncology, and ophthalmology.

A Bright Future Ahead

This strategic partnership not only strengthens SteinCares' position in the biosimilars market but also emphasizes a growing trend of international collaborations aimed at improving patient outcomes across the globe. With effective partnerships, companies like SteinCares and Shilpa Biologicals are paving the way for a new era of healthcare access in Latin America, ensuring that patients will benefit from innovative treatments that were previously out of reach.

As their joint project progresses, stakeholders across the region will be keeping a close eye on the impact this partnership will potentially have on the landscape of affordable healthcare in Latin America.